BMSSC
ABMD

B. Metzler seel. Sohn & Co’s Abiomed Inc ABMD Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,353
Closed -$332K – 765
2022
Q3 		$332K Hold
1,353
– – 0.01% 610
2022
Q2 		$335K Hold
1,353
– – 0.01% 626
2022
Q1 		$448K Sell
1,353
-801
-37% -$247K 0.01% 620
2021
Q4 		$780K Buy
2,154
+757
+54% +$256K 0.01% 481
2021
Q3 		$455K Hold
1,397
– – 0.01% 576
2021
Q2 		$436K Buy
1,397
+190
+16% +$58.3K 0.01% 575
2021
Q1 		$385K Hold
1,207
– – 0.01% 585
2020
Q4 		$391K Buy
+1,207
New +$334K 0.01% 562

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $537M AUM 18.24% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

B. Metzler seel. Sohn & Co's ABMD Position: Q4 2022 in Review

B. Metzler seel. Sohn & Co sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 1,353 shares — an estimated $332K sold.

B. Metzler seel. Sohn & Co first reported a position in ABMD in Q4 2020 and held it in 8 quarters. The position peaked at $780K in Q4 2021. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • B. Metzler seel. Sohn & Co reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • B. Metzler seel. Sohn & Co sold 1,353 Abiomed Inc shares in Q4 2022, an estimated $332K.
  • B. Metzler seel. Sohn & Co first reported a position in Abiomed Inc in Q4 2020 and held it in 8 quarters.
  • B. Metzler seel. Sohn & Co's Abiomed Inc position peaked at $780K in Q4 2021.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q4 2022, filed 13 Feb 2023.